Eliminating government waste, fraud, abuse, and mismanagement is challenging. Every program receives the taxpayer’s money and support from vested interests, and its existence is rarely tied to results. Congress is supposed to provide oversight and accountability but even when hearings are held, they do not usually lead to the consolidation or elimination of programs. In […]
President Donald Trump has made addressing healthcare costs a priority of his second term in office. While this is a noble goal, it is important that this goal is achieved while rejecting foreign price controls. On September 30, 2026, the Center for Medicare and Medicaid Innovation (CMMI) announced it had finalized the Global Benchmark for […]
The establishment of well-intentioned programs that fail to achieve their objectives and waste taxpayer dollars is an unfortunately frequent occurrence in the federal government. A prominent example of such an outcome is the 340B program, created by Section 340B of the Public Health Service Act of 1992, which requires pharmaceutical manufacturers participating in Medicaid to […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
This prudent decision will send a strong message to other state legislatures across the country not to pursue similar legislation.
